Mumbai: Indoco Remedies Limited, a fully integrated, research-based pharma company has acquired 85 percent of equity stake of
the US-based FPP Holding Company, LLC for USD 4 million from Contract
Pharmacal Corp. (“CPC”).
FPP Holding is the holding company of Florida Pharmaceutical Products, LLC which is
based in Florida and engaged in marketing and distribution of generic pharmaceutical
products in the USA.
“This development will facilitate exchange of knowledge and best practices, further
enhancing the overall competitiveness and growth potential of both organizations.
Leveraging FPP’s well-established distribution network, Indoco will have a greater reach and
accessibility to a wider US customer base”, said Aditi Panandikar, Managing Director –
Indoco Remedies Ltd.
Read also: Indoco Remedies AnaCipher CRO gets clearance on Remote Record Assessment from USFDA
Company’s turnover is US$ 200 million.The Company has 9 manufacturing facilities, 6 for FDFs and 3 for APIs, supported by a state-of-the-art R&D
Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including
USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the
Indian and international markets. It generates more than 109 million prescriptions annually from over 3,00,000
doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a brand portfolio
in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals,
Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gyneacology etc. Top Indoco
brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF,
Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM 69, Methycal, Homide, Cal-Aid, etc. On the
international front, Indoco has tie-ups with large generic companies across the globe.
GIPHY App Key not set. Please check settings